The effect of oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel on calcium metabolism.
Fasting plasma and urinary calcium and urinary hydroxyproline are known to rise at the menopause, reflecting increased bone resorption. Oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel are shown to reduce this evidence of increased bone loss. It is concluded that these preparations will be effective in preventing post-menopausal loss of bone.